Abstracts tagged "Lupus"

Abstract Number: 2926 • 2015 ACR/ARHP Annual Meeting
Cytochrome P450 Polymorphisms on Blood Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus
Ji Yeon Lee¹, Min Kyung Chung², Ji Hun Kim², Jung Hee Koh³, Seung Min Jung⁴, Jennifer Lee², Seung-Ki Kwok⁵, Ji Hyeon Ju⁶, Kyung-Su Park⁷ and Sung-Hwan Park², ¹Division of Rheumatology, Department of Internal Medicine, School of Medicine, Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, South Korea, ⁴Division of Rheumatology, Department of Internal Medicine, school of medicine, The catholic university of Korea, Seoul, South Korea, ⁵[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁷Division of Rheumatology, Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Hydroxychloroquine (HCQ) is a safe and effective treatment for systemic lupus erythematosus (SLE), and its blood concentration is known to be closely related to…
Abstract Number: 24 • 2015 ACR/ARHP Annual Meeting
Investigating the Role of Vitamin D in the Transition to Systemic Lupus Erythematosus in Individuals at Risk for the Disease
Kendra A. Young¹, Melissa E. Munroe², Joel M. Guthridge², Diane L. Kamen³, Timothy B. Niewold⁴, Gary S. Gilkeson⁵, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J Wallace⁷, David R. Karp⁸, John B. Harley⁹, Judith A. James¹⁰ and Jill M. Norris¹¹, ¹Epidemiology, University of Colorado Denver, Aurora, CO, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Medicine, Medical University of South Carolina, Charleston, SC, ⁴Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁵Department of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Internal Medicine - Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, ⁹Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹University of Colorado Denver, Aurora, CO
Background/Purpose: Lower vitamin D levels are associated with increased disease activity in systemic lupus erythematosus (SLE) and individuals with SLE have increased prevalence of vitamin…
Abstract Number: 768 • 2015 ACR/ARHP Annual Meeting
The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) Instrument Correlates Between Trained Clinical Investigators and Clinicians
Anca Askanase¹, Teja Kapoor², Cynthia Aranow³, Karen H. Costenbader⁴, Jennifer Grossman⁵, Diane L. Kamen⁶, S. Sam Lim⁷, Mimi Kim⁸, Paola Daly^9,10, Leslie M. Hanrahan¹¹ and Joan T. Merrill¹², ¹NYU School of Medicine, New York, NY, ²Columbia University, New York, NY, ³Feinstein Institute for Medical Research, Mahasset, NY, ⁴Rheumatology, Immunology & Allergy, Brigham & Women's Hospital, Boston, MA, ⁵Rheumatology, UCLA, LA, CA, ⁶Medicine, Medical University of South Carolina, Charleston, SC, ⁷Emory University School of Medicine, Atlanta, GA, ⁸Biostatistics and Research Design Resource, Albert Einstein Coll Med, Bronx, NY, ⁹Lupus Foundation of America, Washington DC, DC, ¹⁰Lupus Foundation of America, Washington, DC, ¹¹Lupus Fnd of America, Washington, DC, ¹²Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Current SLE disease activity measures, such as SLEDAI and BILAG, can be challenging to score and interpret, making them impractical for use in…
Abstract Number: 1115 • 2015 ACR/ARHP Annual Meeting
B Cell-Intrinsic Interferon Gamma Signals Promote the Development of Systemic Lupus Erythematosus By Enhancing the Formation of Spontaneous Autoimmune Germinal Centers
Shaun Jackson, Nicole Scharping, Holly Jacobs, Tanvi Arkatkar, Socheath Khim and David Rawlings, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: Type 1 interferon (IFN) is strongly implicated in lupus pathogenesis, and SLE patients frequently express a “type 1 IFN gene signature”. The type 2…
Abstract Number: 1843 • 2015 ACR/ARHP Annual Meeting
Bloodstream Infections in Systemic Lupus Erythematosus Patients Are Associated with Severe Lupus Flares
José Jiram Torres Ruiz¹, Ana Barrera-Vargas², Rigoberto Ortíz-Hernández², Jorge Alcocer-Varela² and Diana Gómez-Martín², ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Infections are an important cause of mortality and morbidity in systemic lupus erythematosus (SLE) patients. Bloodstream infections (BI), which are especially severe and relatively…
Abstract Number: 2946 • 2015 ACR/ARHP Annual Meeting
Mortality Among SLE Patients in the National Data Bank for Rheumatic Diseases
Kaleb Michaud¹, Sofia Pedro² and Patricia P. Katz³, ¹Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: To investigate risk of mortality among SLE patients cohort in the NDB.Methods: Systemic lupus erythematous (SLE) and non-inflammatory rheumatic disease (NIRD) patients were studied…
Abstract Number: 51 • 2015 ACR/ARHP Annual Meeting
Oral Glucocorticoid Use Is Associated with Osteonecrosis in Adults with Chronic Inflammatory Diseases but Not in Children: A Population-Based Cohort Study
Daniel B. Horton^1,2,3, Kevin Haynes^1,4, Michelle R. Denburg^1,5, Mihir Thacker⁶, Carlos D. Rose², Mary E. Putt¹, Mary B. Leonard⁷ and Brian L. Strom^1,3, ¹Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Pediatrics, Nemours A.I. duPont Hospital for Children, Division of Pediatric Rheumatology, Thomas Jefferson University, Wilmington, DE, ³Rutgers Biomedical and Health Sciences, New Brunswick, NJ, ⁴Clinical Epidemiology, HealthCore, Wilmington, DE, ⁵Pediatrics, Children’s Hospital of Philadelphia, Division of Nephrology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Orthopedics, Nemours A.I. duPont Hospital for Children, Thomas Jefferson University, Wilmington, DE, ⁷Pediatrics, Division of Nephrology, Stanford School of Medicine, Stanford University, Palo Alto, CA
Background/Purpose: Glucocorticoids have long been linked to the development of osteonecrosis, mostly in heavily exposed patients from specialty clinics. We tested the hypothesis that oral…
Abstract Number: 773 • 2015 ACR/ARHP Annual Meeting
Clinical Evaluation of Patients with Positive Antibodies to Extractable Nuclear Antigens but Negative ANA
Megan L. Krause¹, Michael Ettore², Melissa R. Snyder³, Cynthia S. Crowson⁴ and Kevin G. Moder¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ³Laboratory Medicine, Mayo Clinic, Rochester, MN, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose: In the setting of a negative ANA, antibodies to extractable nuclear antigens (ENA) should be correspondingly negative, but alternative clinical scenarios occasionally arise. This…
Abstract Number: 1117 • 2015 ACR/ARHP Annual Meeting
The B Cell Survival Cytokine BAFF Promotes Systemic Lupus Erythematosus Via Activation of TACI, Not BAFF Receptor
Holly Jacobs¹, Christopher Thouvenel¹, Tanvi Arkatkar¹, Nicole Scharping¹, David Rawlings² and Shaun Jackson¹, ¹Seattle Children's Research Institute, Seattle, WA, ²Pediatrics/Immunology, Washington, Seattle, WA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by polyclonal B cell activation and production of class-switched antinuclear antibodies (ANA). Transgenic mice…
Abstract Number: 1844 • 2015 ACR/ARHP Annual Meeting
Risk Factors for Complicated Pneumonia in Systemic Lupus Erythematosus (SLE)
Gabriela García-Guevara¹, Ricardo Ríos-Corzo², Juan Ávila-Vázquez³, John Hernández-Flores⁴, Eduardo Carrillo-Maravilla⁵, Juan Jakez-Ocampo⁶, Hilda Fragoso-Loyo⁷, Luis Llorente⁸ and Yemil Atisha-Fregoso⁹, ¹Vasco de Quiroga #15, Tlalpan, Belisario Domínguez Sección XVI, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ²Escuela de Medicina, Instituto Tecnológico y de Estudios Superiores de Monterrey, Monterrey, Mexico, ³Escuela Nacional de Medicina, Instituto Tecnológico y de Estudios Superiores de Monterrey, Mexico, Mexico, ⁴Escuela de Medicina, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico, ⁵Medicina Interna, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Mexico, ⁷Vasco de Quiroga 15 Col Seccio, INNCMSZ-Departamento de Inmunología y Reumato, Mexico, Mexico, ⁸Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Pneumonia, remains as a main cause of mortality in patients with SLE. In patients without autoimmune disease, scores as Pneumonia Severity Index (PSI) and…
Abstract Number: 2949 • 2015 ACR/ARHP Annual Meeting
Differential Serum Cytokine Profile in Patients with Systemic Lupus Erythematosus and Posterior Reversible Encephalopathy Syndrome: A Single-Center Study
Jorge Alcocer-Varela¹, Diana Gómez-Martín¹, Javier Merayo-Chalico² and Ana Barrera-Vargas¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are susceptible to the development of posterior reversible encephalopathy syndrome (PRES). The main theory about the physiopathology of…
Abstract Number: 208 • 2015 ACR/ARHP Annual Meeting
Neutrophil-Mediated Mechanisms of Drug-Induced Autoimmunity
Jorge Irizarry-Caro¹, Carmelo Carmona-Rivera¹, Elaine Novakovich¹, Venkataraman Subramaniam², Paul Thompson³, Mariana J. Kaplan⁴ and Peter C. Grayson⁵, ¹National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ²Biochemistry and Molecular Pharmacology, University of Massachusetts, Worcester, MA, ³University of Massachusetts, Worcester, MA, ⁴Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD
Background/Purpose: Certain medications are known to induce autoimmune disease in humans, triggering clinical features and autoantibody profiles that mirror idiopathic systemic lupus erythematosus (SLE) and/or…
Abstract Number: 776 • 2015 ACR/ARHP Annual Meeting
Sensitivity of Antinuclear Antibody By Immunofluorescence Testing for Detection of Anti-Ro/SSA Antibodies
Ivan Alcantara-Arreola¹, Nina Tello-Winniczuk² and Alejandro Diaz-Borjon³, ¹Hospital Angeles Lomas, Huixquilucan, Mexico, ²Division of Internal Medicine / Rheumatology, Hospital Angeles Lomas, Huixquilucan, Mexico, ³Med/Div of Rheumatology, Hospital Angeles Lomas, Huixquilucan, Mexico
Background/Purpose: A positive ANA test is a diagnostic criterion for several rheumatic diseases, although it may appear in other autoimmune disorders and healthy individuals. An…
Abstract Number: 1199 • 2015 ACR/ARHP Annual Meeting
The Charla De Lupus (Lupus Chat)® Program: An Evaluation of a Lupus Support Program for Teens, Young Adults and Parents
Melissa T. Flores¹, Jillian A. Rose¹, Roberta Horton¹, Dariana M. Pichardo¹, Lillian Mendez¹ and Lisa F. Imundo², ¹Social Work Programs, Hospital for Special Surgery, New York, NY, ²Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: Research shows that chronic illnesses such as lupus have a multi-level impact on the entire family; it can be challenging for both patients &…
Abstract Number: 1864 • 2015 ACR/ARHP Annual Meeting
H3K4me3 Peak Shape Dictates Transcription and Regulates Differential Expression in SLE
Kathleen E. Sullivan¹, Lihua Shi², Li Song³, Michelle Petri⁴ and Zhe Zhang⁵, ¹Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, ³Allergy Immunology, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Rheumatology, Johns Hopkins University Hospital, Baltimore, MD, ⁵Bioinformatics, Children's Hospital of Philadelphia, Bioinformatics, Philadelphia, PA
Background/Purpose: H3K4me3 is a post-translational modification of histone H3 associated typically with gene activation. We had previously characterized changes in H3K4me3 associated with SLE in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].